Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
M C Benyunes, C Higuchi, A York, C Lindgren, J A Thompson, C D Buckner, A Fefer
Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trialBone Marrow Transplant. 1995 Aug;16(2):283-8.
M Fishman, J P Dutcher, J I Clark, A Alva, G P Miletello, B Curti, Neeraj Agarwal, R Hauke, K M Mahoney, H Moon, J Treisman, S S Tykodi, G Daniels, M A Morse, M K K Wong, H Kaufman, N Gregory, D F McDermott
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM SM registryJ Immunother Cancer. 2019 Mar 27;7(1):84.
M May, C Helke, M Bock, B Hoschke
[Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil]Urologe A. 2004 Sep;43(9):1111-9.
M R Albertini, J A Hank, J H Schiller, M Khorsand, A A Borchert, J Gan, R Bechhofer, B Storer, R A Reisfeld, P M Sondel
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patientsClin Cancer Res. 1997 Aug;3(8):1277-88.
M T Lotze, B Hellerstedt, L Stolinski, T Tueting, C Wilson, D Kinzler, H Vu, J T Rubin, W Storkus, H Tahara, E Elder, T Whiteside
The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapyCancer J Sci Am. 1997 Dec;3 Suppl 1:S109-14.
M T Lotze, M Shurin, C Esche, H Tahara, W Storkus, J M Kirkwood, T L Whiteside, E M Elder, H Okada, P Robbins
Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunityCancer J Sci Am. 2000 Feb;6 Suppl 1:S61-6.
M. Loredana Marcovecchio, 1, Linda S. Wicker, David B. Dunger et al 
PDF
Wellcome Open Research 2020, 09 JUL 2020
Maday O.D., Maday D.Yu., Shcherbuk Yu.A., Kozlov V.K. PDF
From the practice of treating patients with acute odontogenic infection at the hospital stage.
Fundamental science and technology / Сборн. научн. ст. по мат. XII Межд. научно-практ. конф. (14.04.2023, г. Уфа). Ч.3 – Уфа: Изд. НИЦ Вестник науки. — 2023. — С. 84-97.
Mahmoudpour SH, Jankowski M, Valerio L et al. PDF
Sci Rep. 2019 May 9;9(1):7145.
Maki Kobayashi, Katsuhiko Kojima, Kazutaka Murayama et al. PDF
Cancer Sci. 2021 Nov;112(11):4478-4489.
Malin S. Nilsson, Michael Fiegl, Wolfgang Hiddemann et al. PDF
Haematologica. — 2024. — Vol. 109. No. 11.
Malkovska V, Sondel PM.
Prospects for interleukin-2 therapy in hematologic malignant neoplasms.J Natl Cancer Inst Monogr. 1990;(10):69-72. PMID: 2189478.
Maraninchi D, Vey N, Viens P, Stoppa AM et al.
A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.Leuk Lymphoma. 1998 Oct;31(3-4):343-9. doi: 10.3109/10428199809059227. PMID: 9869198.
Marion Leboyer, Marianne Foiselle, Nicolas Tchitchek et al. PDF
Brain, Behavior, and Immunity. 2025. — Vol. 123, January 2025, P. 177-184.
Martín-Lluesma, S. et al. PDF
Annals of Oncology, Volume 35, Issue 10, 860 — 872
Masao Hashimoto, Suresh S. Ramalingam, Ra fi Ahmed. PDF
Trends in cancer. – 2024. – V. 10, Is. 4, Pages 332-346 . DOI: 10.1016/j.trecan.2023.11.008
Mekhail T, Wood L, Bukowski R.
Interleukin-2 in cancer therapy: uses and optimum management of adverse effects.BioDrugs. 2000 Nov;14(5):299-318.
Melissa Bersanelli , Sebastiano Buti , Roberta Camisa et al. PDF
Cancers. – 2014. – September 6(4):2035-2048.
Meng‘en Zhu, Qian Wang, Shaoqiong Zhou et al. PDF 
ZIP
07 July 2020, PREPRINT (Version 1) available at Research Square.
Mertens WC, Banerjee D, al-Mutter N et al.
High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets.Cancer Immunol Immunother. 1995 Nov;41(5):271-9. doi: 10.1007/BF01517214. PMID: 8536272.
Merve Çebi1, Arman Çakar, Hacer Durmu¸s et al. PDF
Eur. J. Immunol. 2024;54:2451268.
Merve Hasanov , Simin Kiany , Marie-Andrée Forget et al. PDF
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma.
OncoImmunology, 14:1, 2546402, DOI: 10.1080/2162402X.2025.2546402
Miao Miao, Xian Xiao, Jiayi Tian et al.
Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study.Реестр клинических исследований США. 3 апреля 2023 г.
Michelle L Janas, Penny Groves, Norbert Kienzle, Anne Kelso
IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferationJ Immunol. 2005 Dec 15;175(12):8003-10.
Mikhailova V.A., Belyakova K.L., Vyazmina L.P. et al PDF
Evaluation of microvesicles formed by natural killer (NK) cells using flow cytometry.
Medical Immunology (Russia). – 2018. – Vol. 20, No 2. – P. 251-254.
Mikhailova V.A., Bazhenov D.O., Belikova M.E. et al. PDF
Interactions of NK Cells and Trophoblast Cells. Methodological Aspects.
Сell Technologies in Biology and Medicine. — No. 2, August. — 2018. — P. 548-553.
Mikhailova V.A., Bazhenov D.O., Viazmina L.P. et al. PDF
Cytotoxic Activity of Peripheral Blood NK Cells towards Trophoblast Cells during Pregnancy.
Cell Technologies in Biology and Medicine. — No. 4, February. — 2019. — P. 567-573.
Miller JS, Tessmer-Tuck J, Blake N et al.
Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.Exp Hematol. 1997 Oct;25(11):1140-8. PMID: 9328450.
Minoru Kobayashi, Hitoshi Ikeda, Akinori Nukui, Kazumi Suzuki, Yasuhiro Sugaya, Masayuki Yuzawa, Tatsuo Morita
Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-alpha, and tegafur-uracil: a single-institution experienceInt J Clin Oncol. 2008 Jun;13(3):257-62.
Miro E. Raeber, Dilara Sahin, Ufuk Karakus, Onur Boyman PDF
MedRxiv, December 4, 2022. Doi: https://doi.org/10.1101/2022.12.02.22283042
Mohamed A Shaker, Husam M Younes
Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapyJ Pharm Sci. 2009 Jul;98(7):2268-98.
Mortara L, Balza E, Bruno A et al. PDF
Front. Immunol. 9:2905. doi: 10.3389/fimmu.2018.02905
Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.Cancer Res. 1986 Feb;46(2):676-83. PMID: 3484431.
Mulé JJ, Yang J, Shu S, Rosenberg SA.
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.J Immunol. 1986 May 15;136(10):3899-909. PMID: 2871106.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.